Erschienen in:
23.02.2022 | Original Article
Long-term prognosis of laparoscopic gastrectomy for patients on antithrombotic therapy: a retrospective cohort study
verfasst von:
Motohira Yoshida, Hiroyuki Egi, Kei Ishimaru, Shigehiro Koga, Satoshi Akita, Satoshi Kikuchi, Hiroki Sugishita, Jun Kuwabara, Yusuke Ogi, Sayuri Matsui, Yuji Watanabe
Erschienen in:
Surgery Today
|
Ausgabe 10/2022
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Few studies have reported on the interactions between gastrectomy and antithrombotic therapy, especially the long-term prognosis. We aimed to clarify the short- and long-term prognosis of gastrectomy for patients on antithrombotic therapy.
Methods
We reviewed the perioperative data and survival rate of patients who underwent laparoscopic distal gastrectomy (LDG) at our institute between 2010 and 2013.
Results
There were 119 patients enrolled in this retrospective study: 31 who were taking antithrombotic drugs (antithrombotic therapy (ATT) group), and 88 who were not (non-ATT group). The mean age was significantly higher in the ATT group than in the non-ATT group. No significant differences were observed in the amount of intraoperative bleeding or blood hemoglobin level after surgery between the groups. Bleeding complications occurred in only one patient from the ATT group, and the postoperative complication rate was comparable between the groups. During follow-up, cerebrovascular or cardiovascular events developed in 19.4% of the ATT group patients and 4.5% of the non-ATT group patients; however, there were no significant differences in the 5-year overall survival rates between the groups (ATT group, 76.9%; non-ATT group, 82.9%).
Conclusions
Antithrombotic therapy did not affect the short-term or long-term prognosis of patients after LDG.